These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24148851)

  • 1. Development and feasibility testing of decision support for patients who are candidates for a prophylactic implantable defibrillator: a study protocol for a pilot randomized controlled trial.
    Carroll SL; McGillion M; Stacey D; Healey JS; Browne G; Arthur HM; Thabane L
    Trials; 2013 Oct; 14():346. PubMed ID: 24148851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description.
    Cheng A; Dalal D; Butcher B; Norgard S; Zhang Y; Dickfeld T; Eldadah ZA; Ellenbogen KA; Guallar E; Tomaselli GF
    J Am Heart Assoc; 2013 Feb; 2(1):e000083. PubMed ID: 23525420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
    Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design.
    Zhang S; Singh B; Rodriguez DA; Chasnoits AR; Hussin A; Ching CK; Huang D; Liu YB; Cerkvenik J; Willey S; Kim YH
    Europace; 2015 Nov; 17(11):1720-6. PubMed ID: 26037794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment.
    van der Heijden AC; van Rees JB; Levy WC; van der Bom JG; Cannegieter SC; de Bie MK; van Erven L; Schalij MJ; Borleffs CJ
    Europace; 2017 Jan; 19(1):72-80. PubMed ID: 28130376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assisting Black Patients With Decision-Making for Implantable Cardioverter Defibrillator Therapy: Qualitative Findings From the Videos to Reduce Racial Disparities in ICD Therapy via Innovative Designs (VIVID) Trial.
    Jackson LR; McKenna K; Corneli A; Dombeck C; Brelsford K; Thomas KL
    Circ Cardiovasc Qual Outcomes; 2024 Jul; 17(7):e010550. PubMed ID: 38864226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.
    Probst V; Boveda S; Sadoul N; Marquié C; Chauvin M; Mondoly P; Gras D; Jacon P; Defaye P; Leclercq C; Anselme F
    Arch Cardiovasc Dis; 2020 May; 113(5):359-366. PubMed ID: 32334981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry.
    Defaye P; Boveda S; Klug D; Beganton F; Piot O; Narayanan K; Périer MC; Gras D; Fauchier L; Bordachar P; Algalarrondo V; Babuty D; Deharo JC; Leclercq C; Marijon E; Sadoul N;
    Europace; 2017 Sep; 19(9):1478-1484. PubMed ID: 28340096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults.
    Hess PL; Matlock DD; Al-Khatib SM
    Clin Cardiol; 2020 Feb; 43(2):187-195. PubMed ID: 31867773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Italian subcutaneous implantable cardioverter-defibrillator survey: S-ICD, why not?
    Botto GL; Forleo GB; Capucci A; Solimene F; Vado A; Bertero G; Palmisano P; Pisanò E; Rapacciuolo A; Infusino T; Vicentini A; Viscusi M; Ferrari P; Talarico A; Russo G; Boriani G; Padeletti L; Lovecchio M; Valsecchi S; D'Onofrio A;
    Europace; 2017 Nov; 19(11):1826-1832. PubMed ID: 28011803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes.
    Santharam S; Hudsmith L; Thorne S; Clift P; Marshall H; De Bono J
    Europace; 2017 Mar; 19(3):407-413. PubMed ID: 27234868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.
    Tan VH; Wilton SB; Kuriachan V; Sumner GL; Exner DV
    Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):164-70. PubMed ID: 24446023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis.
    Piccini JP; Al-Khatib SM; Myers ER; Anstrom KJ; Buxton AE; Peterson ED; Sanders GD
    J Cardiovasc Electrophysiol; 2010 Jul; 21(7):791-8. PubMed ID: 20132397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of routine right parasternal electrocardiographic screening in assessing eligibility for subcutaneous implantable cardioverter-defibrillator.
    Arias MA; Pachón M; Sánchez-Iglesias I; Loughlin G; Martín-Sierra C; Puchol A; Sabatel F; Rodríguez-Padial L
    J Cardiovasc Electrophysiol; 2020 Jan; 31(1):103-111. PubMed ID: 31724763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to patients eligible for screening investigations and insertion of primary prevention implantable cardioverter defibrillators.
    Sadarmin PP; Wong KC; Rajappan K; Bashir Y; Betts TR
    Europace; 2014 Nov; 16(11):1575-9. PubMed ID: 24668515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary rates and outcomes of single- vs. dual-coil implantable cardioverter defibrillator lead implantation: data from the Israeli ICD Registry.
    Leshem E; Suleiman M; Laish-Farkash A; Konstantino Y; Glikson M; Barsheshet A; Goldenberg I; Michowitz Y;
    Europace; 2017 Sep; 19(9):1485-1492. PubMed ID: 27702848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.